Yonsei Med J.  2005 Dec;46(6):759-764.

Anaplastic Thyroid Carcinoma: A Therapeutic Dilemma

• Chang HS
• Nam KH
• Chung WY
• Park CS

Abstract

Anaplastic thyroid carcinoma (ATC) is one of the most malignant human neoplasms and has a grave prognosis. This study gives an update on our experience with this unusual neoplasm, with specific focus on the response to various treatment modalities. Forty-seven patients with histologically proven ATCs were enrolled (19 men, 28 women; mean age, 62.8 years). This number represents 1.5% among a total of 3, 088 thyroid cancers treated between 1977 and 2002. The mean tumor diameter was 8.8 cm, and 22 patients had distant metastasis. Extrathyroidal extension was seen in 26 (89.7%) of the cases that underwent surgery. Treatment modalities adopted could be classified into 5 groups: Group 1, biopsy only; Group 2, biopsy and chemoradiotherapy; Group 3, debulking only; Goup 4, debulking and chemoradiotherapy; Group 5, complete excision and chemoradiotherapy. Survival was calculated from the time of diagnosis, and comparisons of survival were done by log-rank analysis. The mean survival was 4.3 months (range, 1.0-21 months). The mean survival based on treatment modalities were as follows: Group 1 (n = 10), 2.1 months, Group 2 (n = 8) ; 3.6 months; Group 3 (n = 7), 3.0 months; Group 4 (n = 14), 3.5 months, Group 5 (n = 8), 9.4 months. There was no significant difference in survival time between the various types of treatment modalities. Even though a small improvement in survival was observed with complete excision and aggressive multimodality therapy, nearly all ATCs remain unresponsive to ongoing treatment modalities and as such, present a therapeutic dilemma. A more effective treatment regimen should be sought in order to improve survival.

Keyword

Anaplastic thyroid cancer; treatment modalities; treatment outcome

MeSH Terms

Treatment Outcome
Thyroid Neoplasms/mortality/surgery/*therapy
Survival Analysis
Radiotherapy, Adjuvant
Neoplasm Metastasis
Middle Aged
Male
Humans
Female
Combined Modality Therapy
Chemotherapy, Adjuvant
Carcinoma/mortality/surgery/*therapy
Aged, 80 and over
Aged
Adult

Reference

1. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol. 1999; 16:64–69. PMID: 9890741.

2. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997; 79:564–573. PMID: 9028369.

3. Us-Krasovec M, Golouh R, Auerperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996; 40:953–958. PMID: 8842172.

4. Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery. 1991; 110:956–961. discussion 961-3. PMID: 1745983.

5. Tallroth E, Wallin G, Lundwell G, Lowhagen T, Einhorn J. Multimodal treatment in anaplastic giant thyroid carcinoma. Cancer. 1987; 60:1428–1431. PMID: 2441842.

6. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 1987; 60:2372–2375. PMID: 3664425.

7. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001; 25:617–622. PMID: 11369989.

8. Pacheco-Ojeda LA, Martinez AL, Alvarez M. Anaplastic thyroid carcinoma in ecuador: analysis of prognostic factors. Int Surg. 2001; 86:117–121. PMID: 11918236.

9. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol. 2003; 15:78–83. PMID: 12490766.

10. Farnebo L, Tash O, Wallin G. vanHeerden JA, editor. Anaplastic giant cell carcinoma of the thyroid. Common problems in endocrine surgery. 1989. London: Yearbook;p. 33–34.

11. Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck. 1996; 18:36–41. PMID: 8774920.

12. Haigh PI. Anaplastic thyroid carcinoma. Curr Treat Options Oncol. 2000; 1:353–357. PMID: 12057160.

13. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Geopfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990; 66:321–330. PMID: 1695118.

14. Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995; 17:41–47. discussion 47-8. PMID: 7883548.

15. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001; 91:2335–2342. PMID: 11413523.

16. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg. 1998; 22:725–730. PMID: 9606289.

17. Kim HY, Chung KW, Kim HW, Youn YK, Oh SK. Clinical analysis of anaplastic thyroid carcinoma. J Korean Surg Soc. 2001; 61:142–147.

18. Lu WT, Lin JD, Huang HS, Chao TC. Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma? Otolaryngol Head Neck Surg. 1998; 118:728–731. PMID: 9591882.

19. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000; 11:1083–1089. PMID: 11061600.

20. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer. 1991; 67:564–566. PMID: 1985750.

21. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S. The Swedish Anaplastic Thyroid Cancer Group. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. Cancer. 1994; 74:1348–1354. PMID: 8055459.

22. Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 1992; 18:83–88. PMID: 1582515.

23. Lo CY, Lam KY, Wan KY. Anaplastic carcinoma of the thyroid. Am J Surg. 1999; 177:337–339. PMID: 10326855.

24. Rosen IB, Asa SL, Brierley JD. Clark Oh, Duh QY, Kebebew E, editors. Anaplastic carcinoma of the thyroid gland. Textbook of Endocrine Surgery. 2005. 2nd ed. Philadelphia: W.B.Saunders;p. 159–167.

25. Franzen A, Heldin NE. BMP-7 induced cell cycle arrest of anaplastic thyroid carcinoma via p21(CIP1) and p27 (KIP1). Biochem Biophys Res Commun. 2001; 285:773–781. PMID: 11453659.

26. Greenberg VL, Wiliams JM, Cogswell JP, Mendenhall M, Zimmer SG. Histone deacetylase inhibitors promote apoptosis in differential cell cycle arrest in anaplastic thyroid cells. Thyroid. 2001; 11:315–325. PMID: 11349829.

27. Shi Y, Parhar RS, Zou M, Baitei E, Kessie G, Farid NR, et al. Gene therapy of anaplastic thyroid carcinoma with single-chain interleukin-12 fusion protein. Hum Gene Ther. 2003; 14:1741–1751. PMID: 14670125.

28. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg. 1998; 22:569–574. PMID: 9597930.

29. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? Eur J Endocrinol. 2003; 148:395–402. PMID: 12656659.